RGNCY-0092 (FTPI SYT-SSX1 inhibitor)

SOLD OUT!!  E-mail us at info@reagency.co if you are interested in this product.

FTPI is selectively cytotoxic in synovial sarcoma cell lines (Yamato IC50 = 33µM and ASKA IC50 = 39µM).  Cell cycle analysis shows and involvement of an apoptotic mechanism of cell death.  FTPI treatment down regulates SYT-SSX1 and modulates its downstream target genes.  This results in the down regulation of oncogenes involved in EMT such as beta-catenin, PDGFRA, Cyclin D1, Frizzle receptor and EGFR.  Data suggests that FTPI is a potential anti-cancer molecule.


Systematic Name  6-((3-fluorobenzyl)thio)-5-(o-tolyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one

Molecular Weight:  366.41

Formula:  C19H15FN4OS

PMID:  30219714

Tags: Small molecules, Cancer, Apoptosis, RGNCY-0092, SYT-SSX1, Yamato, ASKA, FTP1, SYT, SSX1